Literature DB >> 9058705

Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro.

A M Mirza1, S Ezzat, A A Axelrad.   

Abstract

Previously, we found that, in the myeloproliferative disorder polycythemia vera (PV), circulating erythroid progenitor cells were hypersensitive to insulin-like growth factor I (IGF-I), an effect shown to occur through the IGF-I receptor. Also, in cells of PV patients, the IGF-I receptor was hyperphosphorylated on tyrosine residues under basal conditions, and its tyrosine phosphorylation in response to exogenous IGF-I was strongly augmented. Thus, because IGF-I appeared to play a role in the pathogenesis of PV, we wished to assess its level in the circulation of these patients. Normally, most of the circulating IGF-I is bound to specific high-affinity IGF binding proteins that can regulate its activity. We determined the circulating levels of IGF-I and two of its key binding proteins, IGFBP-1 and IGFBP-3. In two separate experiments, plasma samples from a total of 23 PV patients age- and sex-matched with 41 normal individuals were compared by radioimmunoassay. The levels of IGFBP-1 in patients with PV (37.80 +/- 4.33 microg/L) were more than fourfold higher than in normals (9.34 +/- 1.34 microg/L) or patients with secondary erythrocytosis (9.47 +/- 1.96 microg/L), whereas the plasma concentrations of IGFBP-3 and IGF-I in these patients were similar to those of normal subjects. Because circulating IGFBP-1 levels may be influenced by insulin, we measured the concentrations of insulin in the same samples. Our data showed that the elevation of circulating IGFBP-1 in PV could not be attributed to low levels of insulin in these patients. The substantial increase in concentration of IGFBP-1 was confirmed on ligand blots performed with (125)I-IGF-I. IGFBP-1 can be either inhibitory or stimulatory to the action of IGF-I under different conditions. We reasoned that if IGFBP-1 were stimulatory for erythropoiesis, an elevated IGFBP-1 level could help to explain the increased sensitivity to IGF-I observed in PV. If IGFBP-1 were inhibitory, it might suggest a compensatory mechanism in which a hyperphosphorylated IGF-I receptor in PV might induce a negative modulator of IGF-I action, in this case IGFBP-1. To distinguish between these two hypotheses, we titrated the effect of IGFBP-1 in the presence of IGF-I with respect to erythroid burst formation and found that IGFBP-1 was strikingly stimulatory. The elevated level of IGFBP-1 coupled with its ability to stimulate erythroid burst formation provide an attractive mechanism to account for the increased sensitivity of erythroid progenitor cells to IGF-I and the consequent overproduction of red blood cells characteristic of PV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058705

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PV.

Authors:  Rosemary E Gale
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway.

Authors:  Wei Zhao; Claire Kitidis; Mark D Fleming; Harvey F Lodish; Saghi Ghaffari
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

Review 3.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 4.  Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies.

Authors:  Leopold Ohler; Klaus Geissler; Wolfgang Hinterberger
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

5.  Erythropoietin and IGF-1 signaling synchronize cell proliferation and maturation during erythropoiesis.

Authors:  Zahra Kadri; Carine Lefevre; Olivier Goupille; Tipparat Penglong; Marine Granger-Locatelli; Suthat Fucharoen; Leila Maouche-Chretien; Philippe Leboulch; Stany Chretien
Journal:  Genes Dev       Date:  2015-12-15       Impact factor: 11.361

6.  Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models.

Authors:  Titiksha Basu; Hannah Bertrand; Nikolaos Karantzelis; Albert Gründer; Heike L Pahl
Journal:  Hemasphere       Date:  2021-04-30

7.  Developing Potential Candidates of Preclinical Preeclampsia.

Authors:  Sandra Founds; Xuemei Zeng; David Lykins; James M Roberts
Journal:  Int J Mol Sci       Date:  2015-11-13       Impact factor: 5.923

Review 8.  Type I insulin-like growth factor receptor signaling in hematological malignancies.

Authors:  Deeksha Vishwamitra; Suraj Konnath George; Ping Shi; Ahmed O Kaseb; Hesham M Amin
Journal:  Oncotarget       Date:  2017-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.